ResMed share price higher on Q3 'solid beat'

ResMed had a stronger than expected third quarter and has impressed the market.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares are on the move on Friday morning
  • The sleep treatment company released a strong third-quarter update today
  • ResMed beat the market's expectations on both the top and bottom line

The ResMed Inc. (ASX: RMD) share price is on course to end the week on a positive note.

In morning trade, the sleep treatment company's shares are up 1% to $34.19.

Why is the ResMed share price rising?

Investors have been bidding the ResMed share price higher today after the company released its third-quarter update.

For the three months ended 31 March, ResMed reported a 29% (31% in constant currency) increase in revenue over the prior corresponding period to US$1,116.9 million.

And while its gross margin contracted by 150 basis points to 55.3%, this couldn't stop the company from delivering a 28% increase in income from operations.

This ultimately led ResMed generating operating cash flow of US$282.6 million and diluted earnings per share of US$1.58.

What were the drivers of its growth?

Management revealed that it significantly ramped up production and delivery of its cloud-connected flow generator devices to meet ongoing high demand from customers during the quarter. This resulted in strong device sales growth across its global markets. ResMed CEO, Mick Farrell, commented:

We now have full global availability of our connected AirSense 10 platform, while we continue to ramp production and availability across more geographies of our AirSense 11 platform. The bottom line is this: We can now support global customer demand for CPAP and APAP devices to serve the entire sleep device market. This is great news for physicians, providers, and especially for patients.

Farrell also revealed that its mask and patient interfaces businesses performed well, as did its outside-hospital software-as-a-service business. He added:

We also saw very strong growth in our mask and patient interfaces businesses globally, demonstrating a sustainable focus on patient adherence and resupply. Our outside-hospital software-as-a-service business achieved high-single-digit growth organically and reached well into double-digit growth with a full quarter of contribution from our MEDIFOX DAN acquisition that we closed last November.

How does this compare to expectations?

Goldman Sachs has taken a quick look at the result and notes that the company's revenue growth was comfortable ahead of expectations. This may explain why the ResMed share price is rising as it is today. The broker said:

3Q23 revenue of $1,117m was up +31% cc, an acceleration from +20% in 2Q and +9% in 1Q23, and a solid beat to consensus +23%.

Pleasingly, it was the same for the company's earnings, with ResMed beating on the bottom line. Goldman adds:

Earnings beat +3% as revenue growth compensates for material gross margin contraction.

Goldman currently has a buy rating and $38.00 price target on ResMed shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »